Transperineal MRI-Fusion Prostate Biopsy
More accurate targeting:
MRI identifies suspicious lesions (especially PI-RADS 4–5), and fusion technology helps target those areas precisely
Less dependence on antibiotic prophylaxis:
Because the needle does not traverse the rectum, we use fewer antibiotics and no bowel prep!
Better detection of clinically significant prostate cancer:
Targeted biopsy can improve detection of important cancers compared with systematic sampling alone, particularly in men with a prior negative biopsy
Better access to certain prostate regions:
Transperineal sampling can provide enhanced access to the anterior and apical prostate, areas that can sometimes be undersampled with a transrectal approach
Lower infection risk:
The transperineal route passes through the skin between the scrotum and anus rather than through the rectum, substantially reducing exposure to rectal bacteria and the risk of serious infection/sepsis
Can combine targeted and systematic biopsies:
This provides both MRI-directed sampling and broader prostate sampling, reducing the chance of missing clinically significant disease